Screener / SEC EDGAR /CIK 0001192448 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

GLAUKOS Corp GKOS

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of GKOS's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Apr 13, 2020
Questions asked 2 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 2 numbered comments
  3. 3. Company replies 3 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 18 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2019

2020-04-13 to 2020-05-01 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-05-01
Comparison of Years Ended December 31, 2019 and December 31, 2018 · Research and Development Expenses, page 35
SEC asked
We note on page 69 that the merger with Avedro was intended to expand your portfolio of pipeline products and on page 4 that you expect your research and development expenses and clinical expenditures to increase.
Rest of the question

Please revise future filings to provide more detail for your research and development expenses for each period presented, including but not limited to, by product candidates and/or by indications, as well as by the nature of the expenses. To the extent that you do not track expenses by product candidate, please disclose as such.

GKOS answered
We respectfully acknowledge the Staff’s comment. In our applicable future filings with the Commission, we will provide more detail regarding our research and development expenses for each period presented, including, to the extent such information is available, by product candidates and/or by indications, as well as by the nature of the expenses. With respect to our product candidates, we respectfully advise the Commission that we are not currently able to fully track expenses by product candidate.
Rest of the answer

We will provide disclosure regarding this fact in our applicable future filings with the Commission.

Read in the reply
In its next report

First report after the company's reply of Apr 23, 2020: 10-Q filed May 7, 2020 ↗, against the 10-Q filed Nov 6, 2019 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2020-05-01

Form S-4

2019-10-09 to 2019-10-15 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
Legal and contingenciesDerivatives and hedging
Registration Statement on Form S-4 filed September 17, 2019 · Exclusive Forum, page 261
SEC asked
We note that your forum selection provision identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any "derivative action." Please revise your prospectus to clearly and prominently describe the provision. Describe any risks or other impacts on investors.
Rest of the question

Risks may include, but are not limited to, increased costs to bring a claim and that these provisions can discourage claims or limit investors' ability to bring a claim in a judicial forum that they find favorable. Also disclose whether this provision applies to actions arising under the Securities Act or Exchange Act. In that regard, we note that Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. If the provision applies to Securities Act claims, please also revise your prospectus to state that there is uncertainty as to whether a court would enforce such provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If this provision does not apply to actions arising under the Securities Act or Exchange Act, please tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

GKOS answered
Article X of the Company’s Restated Certificate of Incorporation (the “Glaukos Charter”) provides that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Company, (B) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (C) any action or proceeding asserting a claim arising pursuant
Rest of the answer

to any provision of the Delaware General Corporation Law of the State of Delaware or the Glaukos Charter or the Company’s Amended and Restated Bylaws, or (D) any action or proceeding asserting a claim governed by the internal affairs doctrine. This provision follows established Delaware case law and legislation and is intended to apply to claims arising under Delaware state law. Accordingly, this provision does not apply to claims brought pursuant to the federal securities laws and the rules and regulations thereunder, including the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the Securities Act of 1933, as amended (the “Securities Act”), or any other claim for which the federal courts have exclusive jurisdiction. The Company’s exclusive forum provision will not relieve the Company of its duties to comply with the federal securities laws and the rules and regulations thereunder, and the Company’s stockholders will not be deemed to have waived the Company’s compliance with these laws, rules and regulations.

In response to the Staff´s comment, the Company has added a new risk factor under “Risk Factors —Risks Relating to the Merger” on page 38 of Amendment No. 1 to clarify that the exclusive forum provision in the Glaukos Charter, which will apply to the combined company following the Merger with Avedro as disclosed in the Registration Statement, does not apply to claims brought pursuant to the federal securities laws and the rules and regulations thereunder, including the Securities Act and the Exchange Act, and to identify the related risks of the exclusive forum provision to, and other potential impacts on, investors.

The Company has also supplemented the description of its exclusive forum provision under “Description of Capital Stock—Anti-Takeover Effects of Delaware Law and the Glaukos Charter and Glaukos Bylaws—Exclusive Forum” and “Comparison of Rights of Holders of Glaukos Common Stock and Avedro Common Stock—Exclusive Forum” on pages 265 and 276, respectively, of Amendment No. 1 to make clear for investors that (i) the exclusive forum provision in the Glaukos Charter does not apply to suits brought pursuant to the Exchange Act or Securities Act, and (ii) the Company’s stockholders will not be deemed to have waived the Company’s compliance with the federal securities laws and the rules and regulations thereunder.

In addition, to help the Company’s stockholders understand the scope of the exclusive forum provision going forward, the Company undertakes to include substantially similar disclosure with regard to its exclusive forum provision in its future Exchange Act and Securities Act filings in which such provision is addressed.

Read in the reply

Also in this review: company letter, Oct 15, 2019

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 6 letters filed since 2019-10-09. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GKOS/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.